IP Library Granted Patent US 7,563,457
Granted Patent B2
US 7,563,457 · App. 10/263,271 · Granted Jul 21, 2009

Nanoparticle assembled hollow spheres

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,563,457
App. No.
10/263,271
Granted
Jul 21, 2009
Kind
B2
Abstract

A design strategy for constructing hierarchically structured materials using nanoparticles and synthetic biopolymers has been developed. Block copolypeptides or homopolymer polyelectrolytes are used as structure-directing agents to arrange nanoparticles (composed of metals, metal non-oxides, metal oxides, or organics) into unusual microstructures, such as spheres, “apples” and “cups.” Hollow spheres can be made wherein nanoparticles of one composition are spatially oriented completely interior or exterior to nanoparticles of a second composition. These aggregates contain nanoparticles only in the shell walls, and maintain their hollowness upon calcination. These shapes can also be fabricated into films. These robust materials are anticipated to have great promise in applications that require surface catalysis, magnetic/electronic/optic properties, transport capabilities, and combinations thereof, such as drug delivery, packaging, catalysis, and sensors.

Claims (32)

1. A nanoparticle-containing microsphere comprising:

a. A diblock copolymer, acting as structure directing agent, that binds to a first and second type of nanoparticles;

wherein the copolymer comprises a peptide block having a sequence of about 10-400 positively-charged residues selected from a group consisting of lysine, arginine, and histidine, and a peptide block of about 10-400 cysteine residues;

b. the structure of the agent being such to direct the formation of an inner and outer layer of said microsphere;

c. said inner layer of said microsphere comprising a first type of nanoparticles bound to the cysteine residues of the structure directing agent; and

d. said outer layer of said microsphere coating the inner layer comprising a second type of nanoparticles bound to the positively charged residues of the structure-directing agent;

e. wherein the first type of nanoparticles is selected from the group consisting of semiconductor group II-VI metal non-oxide nanocrystals, gold nanoparticles, silver nanoparticles, platinum nanoparticles, palladium nanoparticles, copper nanoparticles, rhodium nanoparticles, rhenium nanoparticles, nickel nanoparticles, and iridium nanoparticles and primary functionalization thereof to introduce therapeutic or imaging agents; and

f. wherein the second type of nanoparticles is selected from the group consisting of silicon oxide, titanium oxide; aluminum oxide, zirconium oxide, magnesium oxide and-secondary functionalization thereof to introduce a recognition element for in vivo targeting.

2. A nanoparticle-containing microsphere comprising:

a. poly-L-lysine 100-300 or poly(allylamine hydrochloride), acting as structure directing agent, that binds to a first and second type of nanoparticles;

b. the structure of the agent being such to direct the formation of an inner and outer layer of said microsphere;

c. said inner layer of said microsphere comprising a first type of nanoparticles bound to a portion of the structure directing agent; and

d. said outer layer of said microsphere coating the inner layer comprising a second type of nanoparticles bound to another portion of the structure-directing agent;

e. wherein the first type of nanoparticles is selected from the group consisting of group II-IV semiconductor nanocrystals, gold nanoparticles, silver nanoparticles, platinum nanoparticles, palladium nanoparticles, copper nanoparticles, rhodium nanoparticles, rhenium nanoparticles, nickel nanoparticles, and iridium nanoparticles and primary functionalization thereof to introduce therapeutic or imaging agents; and

f. wherein the second type of nanoparticles is selected from the group consisting of silicon oxide, titanium oxide; aluminum oxide, zirconium oxide, magnesium oxide, and secondary functionalization thereof to introduce a recognition element for in vivo targeting.

3. A method of making a nanoparticle-containing microsphere comprising:

a) combining a solution of a diblock copolypeptide,

wherein the diblock acts as structure-directing agent, that binds to a first and second type of nanoparticles and directs the formation of an inner and outer layer of said microsphere,

wherein the copolypeptide comprises a peptide block having a sequence of about 10-400 positively-charged residues selected from a group consisting of lysine, arginine, and histidine, and a peptide block of about 10-400 cysteine residues;

b) with a solution of a first type of nanoparticles for a time and under conditions sufficient for the first type of nanoparticles to bind to the cysteine residues portion of the structure directing agent and self assemble into an inner shell; and

c) adding a solution of a second type of nanoparticles, to the diblock and first type of nanoparticle mixture, of a different type than the first type of nanoparticles, under conditions sufficient for the second type of nanoparticles to bind to the positively charged residue portion of the structure-directing agent and for the second type of nanoparticles to form an outer layer coating the inner layer containing the first type of nanoparticles;

wherein the first type of nanoparticles is selected from the group consisting of semiconductor group II-VI metal non-oxide nanocrystals, gold nanoparticles, silver nanoparticles, platinum nanoparticles, palladium nanoparticles, copper nanoparticles, rhodium nanoparticles, rhenium nanoparticles, nickel nanoparticles, and iridium nanoparticles and primary functionalization thereof to introduce therapeutic or imaging agents; and

wherein the second type of nanoparticles is selected from the group consisting of silicon oxide, titanium oxide; aluminum oxide, zirconium oxide, magnesium oxide and secondary functionalization thereof to introduce a recognition element for in vivo targeting.

4. The method of claim 3 , further comprising performing a calcination step to remove the structure-directing agent.

5. The method of claim 3 , further comprising mixing either one or both of the first and second type of nanoparticles with a citrate solution.

6. A method of making a nanoparticle-containing microsphere comprising:

a) combining a solution of poly-L-lysine 100-300 or poly(allylamine hydrochloride),

wherein the poly-L-lysine 100-300 or poly(allylamine hydrochloride) acts as structure-directing agent, that binds to a first and second type of nanoparticles and directs the formation of an inner and outer layer of said microsphere,

with a solution of a first type of nanoparticles for a time and under conditions sufficient for the first type of nanoparticles to bind portion of the structure directing agent and self assemble into an inner shell; and

b) adding a solution of a second type of nanoparticles, to the diblock and first type of nanoparticle mixture, of a different type than the first type of nanoparticles, under conditions sufficient for the second type of nanoparticles to bind to another portion of the structure-directing agent and for the second type of nanoparticles to form an outer layer coating the inner layer containing the first type of nanoparticles;

wherein the first type of nanoparticles is selected from the group consisting of group II-IV semiconductor nanocrystals, gold nanoparticles, silver nanoparticles, platinum nanoparticles, palladium nanoparticles, copper nanoparticles, rhodium nanoparticles, rhenium nanoparticles, nickel nanoparticles, and iridium nanoparticles and primary functionalization thereof to introduce therapeutic or imaging agents; and

wherein the second type of nanoparticles is selected from the group consisting of silicon oxide, titanium oxide; aluminum oxide, zirconium oxide, magnesium oxide, and secondary functionalization thereof to introduce a recognition element for in vivo targeting.

Assignments (4)
CONFIRMATORY LICENSE Recorded May 19, 2011
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 026305/0197 →
CONFIRMATORY LICENSE Recorded Dec 27, 2010
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 025568/0800 →
CONFIRMATORY LICENSE Recorded Jan 18, 2008
From: NATIONAL SCIENCE FOUNDATION
To: CALIFORNIA, UNIVERSITY OF
Reel/Frame 020388/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2002
From: CHA, JENNIFER; DEMING, TIMOTHY J.; STUCKY, GALEN D.; WONG, MICHAEL S.; BIRKEDAL, HENRIK; BARTL, MICHAEL H.; SUMEREL, JAN L.
To: REGENTS OF THE UNIVERSITY OF, THE
Reel/Frame 013619/0649 →
Continuity (3)
Provisional Application 6032687000 · Oct 2, 2001
Provisional Application 6036093900 · Mar 1, 2002
Related Publication 20030082237A1 · May 1, 2003